Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   36811   clinical trials with a EudraCT protocol, of which   6078   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2017-001313-93
    Sponsor's Protocol Code Number:MN39159
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2018-03-02
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2017-001313-93
    A.3Full title of the trial
    AN OPEN-LABEL, SINGLE-ARM 4-YEAR STUDY TO EVALUATE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB TREATMENT IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS
    ESTUDIO ABIERTO DE UN SOLO GRUPO Y CUATRO AÑOS DE DURACIÓN PARA EVALUAR LA EFECTIVIDAD Y LA SEGURIDAD DEL TRATAMIENTO CON OCRELIZUMAB EN PACIENTES CON ESCLEROSIS MÚLTIPLE PROGRESIVA
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A Study to Evaluate Effectiveness and Safety of Ocrelizumab Treatment in Patients with Progressive Multiple Sclerosis
    Estudio para evaluar la efectividad y seguridad del tratamiento con Ocrelizumab en pacientes con esclerosis múltiple progresiva
    A.4.1Sponsor's protocol code numberMN39159
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorRoche Farma S.A(Soc. Unipersonal) que realiza el ensayo en España y actúa como representante de F. Hoffmann-La Roche LTD
    B.1.3.4CountrySwitzerland
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportF. Hoffmann-La Roche Ltd
    B.4.2CountrySwitzerland
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationF. Hoffmann-La Roche Ltd
    B.5.2Functional name of contact pointTrial Information Support Line-TISL
    B.5.3 Address:
    B.5.3.1Street AddressGrenzacherstrasse 124
    B.5.3.2Town/ cityBasel
    B.5.3.3Post code4070
    B.5.3.4CountrySwitzerland
    B.5.4Telephone number+34913248121
    B.5.5Fax number+34913248195
    B.5.6E-mailspain.start_up_unit@roche.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameOcrelizumab
    D.3.2Product code RO4964913
    D.3.4Pharmaceutical form Concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNOcrelizumab
    D.3.9.1CAS number 637334-45-3
    D.3.9.2Current sponsor codeRO4964913
    D.3.9.3Other descriptive nameOCRELIZUMAB
    D.3.9.4EV Substance CodeSUB121707
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number30
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Progressive multiple sclerosis (PMS)
    Esclerosis múltiple progresiva (EMP)
    E.1.1.1Medical condition in easily understood language
    Multiple sclerosis (MS) is a chronic autoimmune, inflammatory neurological disease of the central nervous system
    La esclerosis múltiple (EM) es una enfermedad neurológica, crónica, autoinmune e inflamatoria del sistema nervioso central.
    E.1.1.2Therapeutic area Diseases [C] - Nervous System Diseases [C10]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.1
    E.1.2Level PT
    E.1.2Classification code 10028245
    E.1.2Term Multiple sclerosis
    E.1.2System Organ Class 10029205 - Nervous system disorders
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10053395
    E.1.2Term Progressive multiple sclerosis
    E.1.2System Organ Class 10029205 - Nervous system disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    • To evaluate the effectiveness of ocrelizumab treatment in patients with PMS disease course
    •Evaluar la efectividad del tratamiento con ocrelizumab en pacientes con evolución de la enfermedad en la EMP.
    E.2.2Secondary objectives of the trial
    • To evaluate the effectiveness of ocrelizumab treatment in PMS patients using a range of patient-relevant measures and advanced magnetic resonance imaging (MRI) outcomes
    • To evaluate the safety and tolerability of ocrelizumab in PMS patients
    •Evaluar la efectividad del tratamiento con ocrelizumab en pacientes con EMP mediante una serie de medidas de interés para el paciente y de criterios de valoración basados en estudios avanzados de resonancia magnética (RM).
    • Evaluar la seguridad y tolerabilidad de ocrelizumab en pacientes con EMP.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    -Age 18-65 years
    -Have a definite diagnosis of PMS
    -Expanded Disability Status Scale (EDSS) <=6.5 at screening
    - Have a length of disease duration since PMS disease symptom onset <=10 years if baseline EDSS <=5.0 and <=15 years if baseline EDSS >5.0
    - Have documented evidence of disability progression independent of relapse activity at any point over the 2 years prior to the screening visit. In case relapse(s) have occurred in the last 2 years, disability progression will have to be considered as independent of relapse activity as per treating physician’s judgment
    -Fulfill at least one of the 21 criteria assessing the evidence of disability progression independent of relapse activity in the last 2 years using the pre-baseline disability progression rating system checklist
    -Have experience of having used a smartphone and connecting a smartphone to Wi-Fi network providers
    -For women of childbearing potential: agreement to use an acceptable birth control method during the treatment period and for at least 6 months after the last dose of study drug
    -For both, PPMS patients according to revised McDonald 2010 criteria and RMS patients meeting criteria for PMS disease course as per Lublin et al. 2014, it will be documented whether or not they fulfill each of the three following McDonald Criteria:
    o Evidence for Dissemination in Space (DIS) in the brain based on >=1 T2 lesion(s) in at least one area characteristic for MS (periventricular, juxtacortical, or infratentorial).
    o Evidence for DIS in the spinal cord based on >=2 T2 lesions in the cord.
    o Positive findings in a cerebrospinal fluid (CSF) specimen
    -Edad comprendida entre los 18 y 65 años
    -Tener un diagnóstico definitivo de EMP
    -EDSS ≤ 6,5 en la selección.
    -Duración de la enfermedad desde el inicio de los síntomas de la enfermedad EMP ≤ 10 años si la EDSS basal es ≤ 5,0 y ≤15 años si la EDSS basal es >5,0.
    -Presentar indicios documentados de progresión de la discapacidad independiente de la actividad de recidiva en cualquier momento durante los 2 años previos a la visita de selección. En caso de que se hayan producido recidivas en los 2 últimos años, la progresión de la discapacidad tendrá que considerarse independiente de la actividad de recidiva a criterio del médico responsable del tratamiento.
    -Cumplimiento de al menos uno de los 21 criterios de evaluación de los signos de progresión de la discapacidad independientes de la actividad de la recidiva en los 2 últimos años utilizando la lista de comprobación del sistema de valoración de la progresión de la discapacidad antes del momento basal
    -Tener experiencia con el uso de un smartphone y su conexión a proveedores de redes Wi-Fi.
    -Mujeres en edad fértil: compromiso de utilizar un método anticonceptivo aceptable durante el período de tratamiento y hasta al menos 6 meses después de la última dosis del fármaco del estudio.
    -En los pacientes con EMPP según los criterios de McDonald de 2010 revisados y los pacientes con EMR que cumplan los criterios de evolución de la enfermedad en la EMP conforme a Lublin y cols. 2014, se documentará si cumplen o no cada uno de los tres criterios de McDonald siguientes:
    o Signos de diseminación en el espacio (DIS) en el cerebro basándose en ≥ 1 lesiones en T2 en al menos una zona característica para la EM (periventricular, yuxtacortical o infratentorial).
    o Signos de DIS en la médula espinal basándose en ≥ 2 lesiones en T2 en la médula espinal.
    o Hallazgos positivos en una muestra de líquido cefalorraquídeo (LCR)
    E.4Principal exclusion criteria
    -Relapsing-remitting multiple sclerosis (RRMS) at screening.
    -Inability to complete an MRI
    -Gadolinium (Gd) intolerance
    -Known presence of other neurological disorders, including but not limited to, the following:
    o History of ischemic cerebrovascular disorders or ischemia of the spinal cord.
    o History or known presence of Central nervous system (CNS) or spinal cord tumor
    o History or known presence of potential metabolic causes of myelopathy
    o History or known presence of infectious causes of myelopathy
    o History of genetically inherited progressive CNS degenerative disorder
    o Neuromyelitis optica.
    o History or known presence of systemic autoimmune disorders potentially causing progressive neurologic disease
    o History of severe, clinically significant brain or spinal cord trauma
    Exclusions Related to General Health
    -Pregnancy or lactation
    -Any concomitant disease that may require chronic treatment with systemic corticosteroids or immunosuppressant’s during the course of the study
    -History or currently active primary or secondary immunodeficiency.
    -Lack of peripheral venous access.
    -Hypersensitivity to ocrelizumab or to any of its excipients.
    -Significant or uncontrolled somatic disease or any other significant disease that may preclude patient from participating in the study.
    -Active infections must be treated and resolved before possible inclusion in the study.
    -Patients in a severely immunocompromised state until the condition resolves
    -Patients with known active malignancies or being actively monitored for recurrence of malignancy
    -Patients who have or have had confirmed progressive multifocal leukoencephalopathy (PML)
    Exclusions Related to Medications
    -All vaccines should be given at least 6 weeks before the first infusion of ocrelizumab. Live/live attenuated vaccines should be avoided during treatment and safety follow-up period until B cells are peripherally repleted
    -Treatment with any investigational agent within 24 weeks of screening or five half-lives of the investigational drug or treatment with any experimental procedures for MS within 24 weeks of screening
    -Previous treatment with B-cell targeted therapies
    -Any previous treatment with alemtuzumab , total body irradiation, or bone marrow transplantation.
    -Previous treatment with natalizumab, daclizumab or fingolimod in the last 8 weeks.
    Previous treatment with natalizumab where PML has not been excluded according to a specific algorithm
    -Patients previously treated with teriflunomide, unless an accelerated elimination procedure is implemented until its completion before screening visit
    -Previous treatment with azathioprine, cyclophosphamide, mycophenolate mofetil or methotrexate in the last 12 weeks.
    -Previous treatment with mitoxantrone, cyclosporine or cladribine in the last 96 weeks.
    -Contraindications to or intolerance of oral or intravenous (IV) corticosteroids, including methylprednisolone administered IV, according to the country label, such as psychosis not yet controlled by a treatment and hypersensitivity to any of the constituents
    -Treatment with fampridine/dalfampridine or other symptomatic MS treatment unless on stable dose for >=30 days prior to screening. Wherever possible, patients should remain on stable doses throughout the treatment period
    Exclusions Related to Laboratory Findings
    -Positive serum β human chorionic gonadotropin (hCG) measured at screening
    -Positive screening tests for hepatitis B or hepatitis C
    Retesting before baseline: any abnormal screening laboratory value that is clinically relevant should be retested only once in order to rule out any progressive or uncontrolled underlying condition. The last value before randomization must meet study criteria
    -Esclerosis múltiple recividante-remitente (EMRR) en la selección.
    -Imposibilidad de someterse a una RM
    -Intolerancia al gadolinio (Gd)
    -Presencia conocida de otros trastornos neurológicos, entre ellos los siguientes:
    o Antecedentes de trastornos cerebrovasculares isquémicos o isquemia de la médula espinal
    o Antecedentes o presencia conocida de un tumor en el SNC o la médula espinal
    o Antecedentes o presencia conocida de posibles causas metabólicas de mielopatía
    o Antecedentes o presencia conocida de causas infecciosas de mielopatía
    o Antecedentes de trastorno degenerativo progresivo en el SNC genéticamente hereditario
    o Neuromielitis óptica.
    o Antecedentes o presencia conocida de trastornos autoinmunitarios sistémicos que puedan causar una enfermedad neurológica progresiva
    o Antecedentes de traumatismo grave y clínicamente importante en el encéfalo o la médula espinal
    Criterios de exclusión relacionados con la salud general
    -Embarazo o lactancia.
    -Cualquier enfermedad concomitante que requiera tratamiento crónico con corticosteroides o inmunodepresores sistémicos durante el estudio.
    -Antecedentes o presencia activa de una inmunodeficiencia primaria o secundaria.
    -Falta de acceso venoso periférico.
    -Hipersensibilidad al ocrelizumab o a alguno de sus excipientes
    -Enfermedad somática significativa o no controlada o cualquier otra enfermedad importante que impida la participación del paciente en el estudio.
    -Las infecciones activas tendrán que ser tratadas y haber remitido antes de una posible inclusión en el estudio.
    -Pacientes con inmunodepresión grave hasta su resolución.
    -Pacientes con tumores malignos activos conocidos o sometidos a vigilancia activa para detectar recurrencia de neoplasias malignas.
    -Pacientes que presentan o han presentado leucoencefalopatía multifocal progresiva (LMP) confirmada
    Criterios de exclusión relacionados con medicamentos
    -Todas las vacunas deben administrarse al menos 6 semanas antes de la primera infusión de ocrelizumab. La administración de vacunas de microorganismos vivos/atenuados debe evitarse durante el tratamiento y el período de seguimiento de la seguridad hasta que los linfocitos B se repongan periféricamente.
    -Tratamiento con cualquier fármaco en investigación en las 24 semanas previas a la selección o el equivalente a cinco semividas del medicamento en investigación o tratamiento con cualquier procedimiento experimental para la EM en las 24 semanas previas a la selección.
    -Administración previa de tratamientos dirigidos a los linfocitos B
    -Cualquier tratamiento previo con alemtuzumab, irradiación corporal total o trasplante de médula ósea.
    -Tratamiento previo con natalizumab, daclizumab o fingolimod en las últimas 8 semanas.
    -Tratamiento previo con natalizumab cuando no se haya descartado LMP según el algoritmo especificado
    -Pacientes tratados previamente con teriflunomida, a menos que se aplique un procedimiento de eliminación acelerada hasta completarlo antes de la visita de selección
    -Tratamiento previo con azatioprina, ciclofosfamida, micofenolato mofetilo o metotrexato en las últimas 12 semanas.
    -Tratamiento previo con mitoxantrona, ciclosporina o cladribina en las últimas 96 semanas.
    -Contraindicaciones o intolerancia a los corticosteroides por vía oral o intravenosa (IV), incluida la metilprednisolona IV, según la ficha técnica del país, como Psicosis no controlada todavía con un tratamiento e Hipersensibilidad a cualquiera de los componentes
    -Tratamiento con fampridina/dalfamipridina u otros tratamientos sintomáticos para la EM, a menos que sea en una dosis estable durante ≥ 30 días antes de la selección. Siempre que sea posible, los pacientes deberán recibir dosis estables durante todo el período de tratamiento.
    Criterios de exclusión relacionados con resultados analíticos
    -Positividad para la subunidad ß de la gonadotropina coriónica humana (hCG) en suero en el período de selección.
    -Positividad en las pruebas de cribado de hepatitis B o hepatitis C
    Repetición de análisis antes del momento basal: habrá que repetir una sola vez cualquier valor analítico anormal en la selección que tenga importancia clínica con el fin de descartar una enfermedad subyacente progresiva o no controlada. El último valor antes de la aleatorización debe cumplir los criterios del estudio.
    E.5 End points
    E.5.1Primary end point(s)
    1. Proportion of patients with no evidence of progression sustained for at least 24 weeks (NEP)
    2. Proportion of patients with NEP and no active disease (NEPAD)
    1.P roporción de pacientes sin signos de progresión mantenida durante al menos 24 semanas (NEP)
    2. Proporción de pacientes con NEP mantenida durante al menos 24 semanas y ausencia de enfermedad activa (NEPAD)
    E.5.1.1Timepoint(s) of evaluation of this end point
    1-2. From baseline to Week 96, Week 96 to Week 192 and baseline to Week 192
    1-2. Desde basal a semana 96, semana 96 a semana 192 y basal a semana 192
    E.5.2Secondary end point(s)
    1. Change from baseline in cognitive function as measured by the symbol digit modalities test
    2. Change from baseline in the patient-reported outcomes including Multiple Sclerosis Impact Scale -29, Multiple Sclerosis Walking scale -12 items, ABILHAND Questionnaire, and Fatigue Scale for Motor and Cognitive (FSMC) function
    3. Mean change from baseline in the EDSS score over the course of the study
    4. Time to onset of first confirmed disability progression (as measured by EDSS) sustained for at least 24 weeks
    5. Time to onset of first >=20% increase in timed 25-foot walk test sustained for at least 24 weeks
    6. Time to onset of first >=20% increase in 9-hole peg test sustained for at least 24 weeks
    7. Proportion of patients with NEP
    8. Proportion of patients with NEPAD
    9. Time to treatment or study discontinuation
    10. Whole brain volume change
    11. Cortical gray matter volume change
    12. Total T2 lesion volume change
    13. Slowly evolving lesion (SEL) change
    14. Change in total T1 Gd+ lesion
    15. Measurement of T1 gadolinium (Gd)-enhancement in new focal T2 lesions, SELs, persistent areas of non-SEL T2 lesions, and normal-appearing brain tissue
    16. Cerebral white matter volume change
    17. Change in Gd-enhancing fluid-attenuated inversion-recovery (FLAIR) meningeal lesions
    18. Spectroscopic MR: measure of the relative signal amplitude of N-acetyl aspartate, and choline to creatine
    19. Measure of phase (iron) rim lesions by T2*
    20. Change in brain tissue integrity as measured by signal mass analysis
    21. Rate and nature of adverse events
    22. Changes in clinical laboratory results
    1. Variación con respecto al momento basal de la función cognitiva medida con la prueba de modalidades de símbolos y dígitos
    2. Variación con respecto al momento basal de los siguientes resultados comunicados por los pacientes incluyendo la Escala de repercusión de la esclerosis múltiple (MSIS-29), Escala de marcha en la esclerosis múltiple (MSWS-12), Cuestionario ABILHAND y Escala de fatiga para funciones motoras y cognitivas (FSMC)
    3. Variación con respecto al momento basal de la puntuación obtenida en la Escala ampliada del estado de discapacidad (EDSS) durante el transcurso del estudio.
    4. Tiempo transcurrido hasta el inicio de la primera PCD (Medida por EDSS) mantenida durante al menos 24 semanas.
    5. Tiempo transcurrido hasta el inicio del primer aumento del 20% o más en la prueba de T25FWT mantenido durante al menos 24 semanas
    6. Tiempo transcurrido hasta el inicio del primer aumento del 20% o más en la prueba de 9HPT mantenido durante al menos 24 semanas
    7. Proporción de pacientes con NEP
    8. Proporción de pacientes con NEPAD
    9. Tiempo transcurrido hasta la suspensión del tratamiento o hasta la retirada del estudio
    10. Variación del volumen cerebral total
    11. Variación del volumen de la sustancia gris cortical
    12. Variación del volumen total de lesiones en T2
    13. Variación de las lesiones de evolución lenta (LEL)
    14. Variación de las lesiones totales realzadas con Gd+ en T1
    15. Medición del realce con gadolinio (Gd) en T1 de nuevas lesiones focalizadas en T2, LEL, zonas persistentes de lesiones en T2 distintas de las LEL y tejido cerebral de aspecto normal
    16. Variación del volumen de la sustancia blanca cerebral
    17. Variación de las lesiones meníngeas con inversión-recuperación y atenuación de líquidos (FLAIR) realzadas con Gd.
    18. RM espectrométrica: medición de la amplitud de señal relativa del N-acetil-aspartato y de la colina respecto a la creatina
    19. Medición de lesiones con borde de fase en T2
    20. Variación de la integridad del tejido cerebral mediante análisis de masas de las señales
    21. Tasa y naturaleza de acontecimientos adversos
    22. Variación en los resultados de los análisis clínicos
    E.5.2.1Timepoint(s) of evaluation of this end point
    1-3. From baseline to Weeks 48, 96, 144, 192
    4-6. From baseline to Week 192
    7-8. From Week 24 to Week 96, Week 24 to Week 192 and Week 48 to Week 192
    9. From baseline to Week 192
    10-20. From baseline to Weeks 48, 96, 144, 192
    21-22. From baseline to Week 192
    1-3. Desde basal a las semanas 48, 96, 144, 192
    4-6. Desde basal a la semana 192
    7-8. Desde la semana 24 a la semana 96, semana 24 a la semana 192 y semana 48 a la semana 192
    9. Desde basal a la semana 192
    10-20. Desde basal a las semanas 48, 96, 144, 192
    21-22. Desde basal a la semana 192
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial1
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned4
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA79
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Algeria
    Bosnia and Herzegovina
    Brazil
    Canada
    Colombia
    Costa Rica
    Czech Republic
    Denmark
    Egypt
    France
    Guatemala
    Hungary
    Ireland
    Italy
    Kuwait
    Lebanon
    Mexico
    Morocco
    Netherlands
    Panama
    Poland
    Russian Federation
    Saudi Arabia
    Spain
    United Arab Emirates
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The end of the study is defined as the last patient last visit in the B-cell monitoring of the follow-up period.
    El final del estudio se define como la última visita del último paciente durante la vigilancia de los linfocitos B del período de seguimiento.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years6
    E.8.9.1In the Member State concerned months6
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial years6
    E.8.9.2In all countries concerned by the trial months6
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 600
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state15
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 374
    F.4.2.2In the whole clinical trial 600
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    The Sponsor will offer continued access to Sponsor study drug (ocrelizumab) free of charge to eligible patients in accordance with the Roche Global Policy on Continued Access to Investigational Medicinal Product, as outlined below. Please refer to section 4.3.5 of the protocol.
    El promotor ofrecerá acceso continuado al fármaco del promotor del estudio (ocrelizumab) gratuitamente a los pacientes elegibles de acuerdo con la política global de acceso continuado a medicamentos en investigación tal y como se describe debajo. Por favor refiérase a la sección 4.3.5 del protocolo
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2018-05-11
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2018-05-10
    P. End of Trial
    P.End of Trial StatusOngoing
    As of 1.2.2020, the UK is no longer an EU Member State. However, EU law still applies to the UK during the transition period
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2020 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA